From neuroprotecting agents to the concept of modulating treatment in the evolutionary course of brain diseases;Des agents neuroprotecteurs au concept de traitement modulateur du cours évolutif des maladies cérébrales

Therapie

Volumn 62, Issue 6, 2007, Pages 463-472

  Bordet, Régis ^a,o   Lestage, Pierre ^b   Onteniente, Brigitte ^c   Bouhours, Philippe ^d   Marlangue, C Charriaut ^e   Chollet, François ^c   Fouchard, Marie ^f   Goni, Sylvia ^g   Hommel, C Marc ^h   Lacomblez, Lucette ⁱ   Marquet, Thierry ^g   Nieoullon, André ^j   Pruss, Rebecca ^k   Quintin, P ^l   Rascol, Olivier ^m   Stanko, Bruno ⁱ   Vray, Muriel ⁿ  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c INSERM   (France)

^d Janssen Cilag   (France)

^e CNRS   (France)

^f Dohme Chibret Centre de Recherche Riom   (France)

^g Lunbeck   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j Université Pierre et Marie Curie   (France)

^k Trophos SA   (France)

^l Lilly SA   (France)

^m UNIVERSITÉ PAUL SABATIER   (France)

ⁿ INSTITUT PASTEUR   (France)

^o UNIV LILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DISEASE; CELL ACTIVITY; CELL DEATH; DISEASE COURSE; HUMAN; MENTAL DISEASE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPATHY; NEUROPROTECTION; PREDICTION; PRIORITY JOURNAL; PRIVATE PRACTICE; REVIEW; TECHNIQUE; VALIDATION STUDY;

EID: 48749103191     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007077     Document Type: Article

References (33)

1. Liebeskind DS, Kasner SE. Neuroprotection for ischaemic stroke. An unattainable goal ? CNS Drugs 2001; 15: 165-74
2. Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic ? An industry perspective. Clin Exp Pharmacol Physiol 2002; (29): 1030-4
3. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Rev Neurosci 2004; (5): 677-85
4. Pitkänen A. Clinical trial in neuroprotection. Drugs 2003; (6): 200-3
5. Marcilhac A. Intracellular signalling pathways, apoptosis and neurodegenerative diseases. Psychol Neuropsychiatr Viellissement 2004; (2): 203-14
6. Gantz LA, Gilmore JH, Lieberman JA, Jarskog LF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 2006; (81): 47-63
7. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; (443): 780-6
8. Vajda FJE. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002; (9): 4-8
9. Ferriero DM. Protecting neurons. Epilepsia 2005; 46 (suppl 7): 45-51
10. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection : a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr 2007; 12 (suppl. 4): 1-13
11. Lipton SA, Rosenberg PA. Excitatory amino acids as a common pathway for neurologic disorders. N Engl J Med 1994; 330 : 613-22
12. Rosenblad C. Growth factor treatment of neurodegenerative disorders: new developement pave the way to clinical success. Invest Drugs 2004; (7): 243-8
13. Martino G. How the brain repairs itself: new therapeutic startegies in inflammatory and degenerative CNS disorders. Lancet Neurology 2004; (3): 372-8
14. Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? J Neurol Neurosur Psychiatry 2002; (72): 152-61
15. EMEA. Slowing the progression of neurodegenerative diseases: medicinal products clinical development. EMEA/512562/2006
16. Lees KR. Neuroprotection. Br Med Bull 2000; (56): 401-12
17. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 1999; (22): 535-40
18. Conforti L, Adalbert R, Coleman MP. Neuronal death: where does the end begin ? Trends Neurosci 2007; (30): 159-66
19. Schapira AHV, Olanow CW. Neuroprotection in Parkinson's disease. Mysteries, myths, and misconceptions. JAMA 2004; (291): 358-64
20. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; (33): 2123-36
21. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury. Lancet Neurology 2002; (1): 383-6
22. Fisher M, Albers GW, Donnan GA, Furlan AJ, et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry Roundtable. Stroke 2005; (36): 1808-13
23. Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol 2003; (2): 215-20
24. Lees KR, Zivin JA, Ashwood T, Davalos A, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; (354): 588-600
25. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007; (61): 396-402
26. Deplanque D, Masse I, Lefebvre C, Libersa C, et al. Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology 2006; (67): 1403-10
27. Chitravas N, Dewey HM, Nicol MB, Harding DL, et al. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007; (68): 1687-93
28. Borroni B, Premi E, Di Luca M, Padovani A. Combined biomarkers for early Alzheimer disease diagnosis. Curr Med Chem 2007; (14): 1171-8
29. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; (2): 605-13
30. Klunk W, Engler H, Nordberg A, Wang Y, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; (55): 306-19
31. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology 2007; (6): 56-62
32. Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Trans Suppl 2006; (71): 123-132
33. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 2003; 53 (suppl 3): S110-S119